Technical Analysis for FOLD - Amicus Therapeutics, Inc.

Grade Last Price % Change Price Change
F 9.6 0.10% 0.01
FOLD closed up 0.1 percent on Thursday, May 6, 2021, on 77 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical FOLD trend table...

Date Alert Name Type % Chg
Stochastic Reached Oversold Weakness 0.00%
Earnings Movers Other 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish 0.10%
Earnings Movers Other 0.10%
Fell Below 20 DMA Bearish -1.08%
Fell Below 50 DMA Bearish -1.08%
Multiple of Ten Bearish Other -1.08%
Gapped Down Weakness -1.08%
Shooting Star Candlestick Bearish -6.61%
Older End-of-Day Signals for FOLD ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 1% about 19 hours ago
Fell Below Previous Day's Low about 19 hours ago
60 Minute Opening Range Breakdown about 19 hours ago
Up 1% about 20 hours ago
Down 2 % 1 day ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Amicus Therapeutics, Inc. Description

Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs known as pharmacological chaperones. It develops pharmacological chaperones as next-generation medicines for a range of rare and orphan diseases with a focus on improved therapies for lysosomal storage disorders. The company's development programs include small molecules as monotherapy treatments for Fabry and other lysosomal storage diseases, and enzyme replacement therapy (ERT). Its chaperone-advanced replacement therapy programs comprise chaperones co-administered with currently marketed ERTs, as well as proprietary therapeutic enzymes co-formulated with pharmacological chaperones as next-generation ERTs. The company's primary product includes migalastat HCl, a product candidate for Fabry disease that is in Phase III global registration studies for patients with genetic mutations. Its products also comprise AT2220, which has completed Phase II safety used for the treatment of Pompe disease; and AT3375 and afegostat tartrate that are in preclinical studies used for treating Gaucher disease. The company has strategic collaboration with GlaxoSmithKline PLC to develop and commercialize migalastat HCl. Amicus Therapeutics, Inc. was founded in 2002 and is based in Cranbury, New Jersey.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Rare Diseases Enzymes Glaxosmithkline Orphan Disease Orphan Diseases Inborn Errors Of Metabolism Lipid Storage Disorders Enzyme Replacement Therapy Fabry Disease Gaucher Disease Lysosomal Storage Disorder Orphan Drugs Lysosomal Storage Disorders Pompe Disease Protein Folding Rare And Orphan Diseases

Is FOLD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 25.39
52 Week Low 8.83
Average Volume 2,887,311
200-Day Moving Average 16.07
50-Day Moving Average 10.12
20-Day Moving Average 9.85
10-Day Moving Average 9.94
Average True Range 0.44
ADX 20.5
+DI 21.69
-DI 24.85
Chandelier Exit (Long, 3 ATRs ) 9.18
Chandelier Exit (Short, 3 ATRs ) 10.34
Upper Bollinger Band 10.48
Lower Bollinger Band 9.22
Percent B (%b) 0.3
BandWidth 12.74
MACD Line -0.18
MACD Signal Line -0.22
MACD Histogram 0.0393
Fundamentals Value
Market Cap 2.5 Billion
Num Shares 261 Million
EPS -2.13
Price-to-Earnings (P/E) Ratio -4.51
Price-to-Sales 24.35
Price-to-Book 18.91
PEG Ratio -0.18
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.04
Resistance 3 (R3) 10.03 9.88 9.96
Resistance 2 (R2) 9.88 9.77 9.88 9.94
Resistance 1 (R1) 9.74 9.70 9.67 9.75 9.91
Pivot Point 9.59 9.59 9.55 9.59 9.59
Support 1 (S1) 9.45 9.48 9.38 9.46 9.29
Support 2 (S2) 9.30 9.41 9.30 9.26
Support 3 (S3) 9.16 9.30 9.24
Support 4 (S4) 9.17